News

Phase III outcomes bode well for novel hyperkalemia therapies


 

EXPERT ANALYSIS FROM THE HFSA ANNUAL SCIENTIFIC MEETING

References

In the subsequent extended phase of the study, patients on ZS-9 t.i.d. in the acute phase were rerandomized to once-daily ZS-9 or placebo for 12 days. Patients on ZS-9 at 5 g or 10 g once daily maintained normokalemia, while those switched to placebo became hyperkalemic once again by day 12, according to Dr. El-Shahawy of the Academic Medical Research Institute, Los Angeles.

The side-effect profile of ZS-9 was similar to that of placebo, with no significant hypokalemia or GI side effects being noted, he added.

A large, long-term study of ZS-9 for maintenance of normokalemia is ongoing.

Dr. Fonarow noted that another, entirely different approach to reducing the risk of hyperkalemia involves the development of novel, nonsteroidal, cardioselective mineralocorticoid receptor antagonists.

He cited a promising phase II study of one such agent, known for now as BAY 94-8862. That study was conducted in patients with heart failure and mild to moderate chronic kidney disease. Patients assigned to the novel agent had significantly smaller rises in serum potassium than those randomized to spironolactone. Yet BAY 94-8862 reduced levels of B-type natriuretic peptide, amino-terminal brain natriuretic peptide, and albuminuria at least as much as did spironolactone, and with significantly lower rates of worsening renal failure (Eur. Heart J. 2013;34:2453-63).

Once new and better therapies for hyperkalemia enter clinical practice, Dr. Fonarow said, the priorities will be to get patients on RAAS inhibitor therapy who should be on it but now aren’t, as well as to augment dosing up to target levels in those now on suboptimal doses. But access to improved treatments for hyperkalemia also opens the door to another intriguing possibility.

“Could the ability to raise doses of RAAS inhibitors even higher than current target doses without causing hyperkalemia further enhance remodeling and improve clinical outcomes? That could indeed be the case. It’s something we’ll want to test in prospective trials,” he said.

Dr. Fonarow reported serving as a consultant to and/or advisory board member for Medtronic, Novartis, Johnson & Johnson, Bayer, and Amgen. Dr. El-Shahawy is on an advisory board for ZS Pharma and has received research grants from that company as well as Amgen, GlaxoSmithKline, Celgene, and Abbvie. Dr. Pitt reported serving as a consultant to Pfizer, Bayer, Lilly, Relypsa, and Sarfez.

bjancin@frontlinemedcom.com

Pages

Recommended Reading

Should LCZ696 receive a level I indication?
MDedge Family Medicine
CardioMEMS heralds new proactive era in heart failure management
MDedge Family Medicine
Myocardial geometry, function altered in obese children
MDedge Family Medicine
Heart failure hospitalizations jump after major holidays
MDedge Family Medicine
Hospitalists shine in study of heart failure outcomes
MDedge Family Medicine
Advanced practice registered nurses in cardiology
MDedge Family Medicine
Androgen-deprivation therapy linked to cardiac death
MDedge Family Medicine
Four lifestyle changes might prevent 40% of heart failure
MDedge Family Medicine
Cancer treatment–induced cardiotoxicity greatly underappreciated
MDedge Family Medicine
Who will get cancer treatment-induced cardiotoxicity?
MDedge Family Medicine